Cybin Moves Forward With Clinical Trial On Psilocybin Oral Film
Cybin Inc. (NEO: CYBN) (OTCQB:CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, announced on Tuesday it has received initial clearance to begin a Phase IIa clinical trial on psilocybin for patients suffering from major depressive disorders (MDD).
The head-to-head study will test Cybin’s proprietary sublingual psilocybin formulation against a 25mg psilocybin capsule on 40 patients.
The trial has been approved by a review board at the University of the West Indies in Jamaica, where the research will be undertaken. The company still awaits final confirmation by Jamaica’s Ministry of Health to begin testing the product on human subjects.
Cybin Granted IRB Approval for Phase II Clinical Trials of its Sublingual Psilocybin Formulation for the Treatment of Major Depressive Disorder biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Psyched: MindMed And Compass Q1 Earnings, FDA Approves Therapists Taking MDMA, Wesana Health Goes Public
Compass Pathways (NASDAQ:CMPS) and
MindMed (NASDAQ:MNMD) remain the only two companies in psychedelics to reach a major U.S. stock exchange. Both companies presented net losses associated with R&D expenses, as entities in the space race towards gaining ground in a sector that still hasn’t reached early maturity or profitability.
Both companies presented strong cash positions to advance their research pipelines.
Compass, Pressing On Psilocybin: Compass highlighted the issuing of two new patents and a post-quarter equity financing round of $144 million.
牙买加发布疫情防控新措施 中使馆发提醒-中国侨网 chinaqw.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from chinaqw.com Daily Mail and Mail on Sunday newspapers.